Aurobindo Injectables Unit Falls Foul Of FDA But Analysts Hopeful

Aurobindo Pharma Ltd, India’s third-largest drug company by sales, has run into trouble with the US Food and Drug Administration, which has issued nine observations on its key sterile injectables unit in southern India, but analysts are confident there will be only a limited commercial impact.

production line
FDA OBSERVATIONS FOR AUROBINDO

More from India

More from Focus On Asia